Pulmonx (4NI) AI Stock Analysis

0 Followers

Pulmonx

(Frankfurt:4NI)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong growth and gross marginsRapid revenue expansion alongside consistently high gross margins indicates attractive product economics and growing adoption of the Zephyr platform. If sustained, this combination can provide increasing gross-profit resources to fund commercial investment and improve operating leverage over the next several quarters.

Negative Factors

Persistent cash burn and lossesOngoing negative cash generation means Pulmonx has not yet converted revenue growth and high gross margins into self-funded operations. Continued losses can require additional financing or constrain investment, leaving the company financially exposed until operating leverage produces sustainable cash-flow breakeven.

Pulmonx (4NI) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 129.78M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -3.0
Beta (1Y): 1.53
Revenue Growth: -8.07%
EPS Growth: 32.11%
Country: Germany
Employees: 296
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Pulmonx Business Overview & Revenue Model

Company Description

Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically...

Pulmonx Earnings Call Summary

Earnings Call Date:Oct 27, 2026(Q3-2026)|% Change Since:42.35%|Next Earnings Date:Feb 24, 2027

Earnings Call SentimentPositive

The call was strongly constructive. Pulmonx returned to year-over-year revenue growth in both the U.S. and international businesses, improved gross margin, reduced operating expenses and losses, reiterated its full-year revenue outlook, and reported progress in its sales organization, clinical programs, China restart, and liquidity position. The main challenges were the relatively inexperienced salesforce, continued cash utilization and net losses, uncertainty around China's shipment timing, and the lack of 2027 guidance.

Positive Updates

Return to Global Revenue Growth

Third-quarter 2026 total worldwide revenue was $22.8 million, up 6% from $21.5 million in the prior-year period on both a reported and constant-currency basis. This was Pulmonx's first return to global year-over-year growth since management rejoined the company last year.

Negative Updates

Shorter and Less Experienced U.S. Salesforce Tenure

Due to turnover, the mean tenure of the U.S. sales organization declined from about 3 years approximately a year and a half ago to about 1.8 years currently, while median tenure is about 1.2 years. Management described the organization as being on the junior side and noted a high degree of variability in the time required to bring representatives up to speed.

Company Guidance

Pulmonx reiterated full year 2026 revenue guidance of $90 million to $92 million, now expects full year 2026 gross margin to be approximately 77%, operating expenses to fall between $108 million and $109 million, inclusive of approximately $14 million of noncash stock based compensation expense, and cash burn to be roughly $22 million, which would be a 30% reduction from our cash burn in 2025. Management expects year-over-year growth to continue for the remainder of the year, China shipments to resume by early next year, and CONVERT II IDE trial enrollment to be completed in the back half of next year; it expects AeriSeal to be commercial in Europe in 2027, with material revenues out of Europe with AeriSeal in 2028. Management said it is committed to sustaining double digit growth, expects OpEx to increase by maybe a few percent moving forward, expects to stay above 75% in terms of our gross margin profile, guides to about 40 a year in new accounts, and expects modest increases in the number of territories opportunistically.

Pulmonx Risk Analysis

Pulmonx disclosed 83 risk factors in its most recent earnings report. Pulmonx reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Pulmonx Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:4NI against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
APYX	53Neutral	$123.42M	-15.17	-70.78%	―	24.35%	46.90%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TELA	48Neutral	$36.11M	-1.27	425.91%	―	1.46%	15.79%
XTNT	41Neutral	$38.57M	-3.38	-23.45%	―	-14.27%	-132.84%
SRTS	36Underperform	$54.32M	-3.64	-34.09%	―	-53.40%	-1719.88%
ICCM	34Underperform	$2.71M	-0.11	-174.26%	―	41.62%	20.47%

* Healthcare Sector Average

Performance Comparison

DE:4NI and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:4NI	Pulmonx Corporation	2.42	0.76	45.78%
APYX	Apyx Medical	3.00	-1.07	-26.29%
XTNT	Xtant Medical Holdings Inc	0.28	-0.38	-58.03%
SRTS	Sensus Healthcare, Inc.	3.41	-1.05	-23.54%
TELA	Tela Bio, Inc.	0.94	-0.17	-15.23%
ICCM	Icecure Medical Ltd.	0.74	-20.56	-96.52%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Pulmonx AI Stock Analysis